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Summary. There is experimental evidence that inhi- 
bition of cyclooxygenase with nonsteroidal nti-in- 
flammatory drugs may decrease cholesterol gall- 
stone formation and mitigate biliary pain in gall- 
stone patients. The mechanisms by which NSAIDs 
exert these effect are unclear. In a prospective, con- 
trolled clinical trial we examined the effects of oral 
indomethacin on the composition of human gall- 
bladder bile. The study included 28 patients with 
symptomatic holesterol or mixed gallstones. Of 
these, 8 were treated with 3 x 25 mg indomethacin 
daily for 7 days prior to elective cholecystectomy 
while 20 received no treatment and served as con- 
trols. Bile and tissue samples from the gallbladder 
were obtained during cholecystectomy. In- 
domethacin tissue levels in the gallbladder mucosa, 
as assessed by HPLC, were 1.05_+0.4 ng/mg wet 
weight, a concentration known to inhibit effectively 
cyclooxygenase activity. Nevertheless, no differ- 
ences between the treated and untreated groups 
were found in the concentrations of biliary mucus 
glycoprotein (0.94___ 0.27 versus 0.93 ___ 0.32 mg/ml) 
or total protein (5.8 +0.9 versus 6.4+ 1.3 mg/ml), 
cholesterol saturation (1.3 _+ 0.2 versus 1.5 +_ 0.2), or 
nucleation time (2.0 +_ 3.0 versus 1.5 + 2.0 days). 
However, biliary viscosity, measured using a low- 
shear rotation viscosimeter, was significantly lower 
in patients receiving indomethacin treatment 
(2.9+0.6 versus 5.6_+ 1.2 mPa.s; P<0.02). In con- 
clusion, in man oral indomethacin decreases bile 
viscosity without alteration of bile lithogenicity or 
biliary mucus glycoprotein content. Since mucus 
glycoproteins are major determinants of bile vis- 
cosity, an alteration in mucin macromolecular 
composition may conceivably cause the in- 
domethacin-induced decrease in biliary viscosity 
and explain the beneficial effects of nonsteroidal 
anti-inflammatory drugs in gallstone disease. 
Abbreviation: NSAIDs = nonsteriodal anti-inflammatory drugs 
* Dedicated to Prof. Dr. G. Paumgartner on the occasion of 
his 60th birthday 
Key words: Biliary mucus - Nonsteroidal anti-in- 
flammatory drugs - Cholesterol nucleation time 
In animal models of cholesterol gallstone disease 
nonsteroidal anti-inflammatory drugs (NSAIDs) 
decrease the tendency of bile to form gallstones 
[10]. The mechanisms responsible for this effect of 
NSAIDs are unclear. Inhibition of mucus secretion 
has been proposed as a potential mode of action. 
This view is based on the observation that in a 
number of animal models mucus hypersecretion is 
observed before crystal formation [11], and that in 
the prairie dog aspirin inhibits both cholesterol 
crystal formation and mucus secretion [10]. Recent 
studies on prairie dog gallbladder explants [15], 
however, failed to show an effect of aspirin on mu- 
cus secretion in concentrations which effectively in- 
hibit prostaglandin synthesis. Furthermore, the rel- 
evance of the data collected in animal experiments 
for cholesterol gallstone disease in man is unclear. 
Studies in gallstone patients uggest hat under as- 
pirin treatment gallstone formation is reduced both 
during weight loss [2] and after successful litholytic 
therapy [7]. A recent prospective study by Rhodes 
et al [16] showed that in gallstone patients aspirin 
decreases mucus synthesis without a reduction in 
the mucus concentration of bile. 
The present study was designed to define the 
effect of oral indomethacin on lithogenicity of bile 
in patients with cholesterol gallstone disease. To 
seek a better understanding of the mechanisms in- 
volved in the action of NSAIDs in gallstone disease 
a detailed analysis of bile was performed, including 
measurement of biliary lipids, proteins, mucus gly- 
coproteins, and viscosity. Finally, to determine 
whether indomethacin treatment is sufficient to 
achieve effective drug levels in the tissue, in- 
domethacin tissue concentrations were measured 
in the gallbladder mucosa. These measurements al-
so served as index for patient compliance. 
Material and methods 
Experimental design and patients 
The study was designed as a prospective, controlled 
clinical trial. Twenty-eight patients were studied. 
Exclusion criteria were acute cholecystitis with ob- 
struction of the cystic duct, gastroduodenal ulcera, 
or hypersensitivity o indomethacin. Twenty pa- 
tients received no treatment and served as controls. 
Eight gave informed consent o be treated with in- 
domethacin 25 mg three times daily for 7 days pri- 
or to cholecystectomy and finished the full course 
of the 7-day treatment. Age, sex, number of gall- 
stones and cholesterol content of gallstones of the 
patients in both groups are listed in Table 1. 
Collection of samples 
Bile was collected uring cholecystectomy by com- 
plete aspiration of gallbladder bile with a 16-G 
needle. Aspiration was performed immediately af- 
ter ligation of the cystic duct. Samples were kept 
under anaerobic onditions and processed within 
30 min after aspiration. Aspirates contaminated 
with blood were not used. From the corpus of the 
gallbladder 2 x 1 x cm tissue samples were taken, 
frozen in liquid nitrogen and stored at -30°C. 
Indomethacin tissue levels 
To determine compliance and to control for in- 
terindividual differences in the absorption of in- 
domethacin into the gallbladder mucosa, in- 
domethacin tissue levels were measured in homog- 
enized samples of the gallbladder mucosa using 
HPLC in a modified method as described by 
Shankar et al 1988 [18]. Briefly, samples of the gall- 
bladder wall (2 cm 2) obtained uring cholecystecto- 
my were dissected sharply into the mucosal and 
muscular layer. The mucosa was homogenized us- 
ing an Ultra Turrax T25 Homogenizer diluted with 
phosphate buffer and incubated for 2 h in a papain, 
cysteic acid, and EDTA solution to ensure com- 
plete release of indomethacin from the tissue ma- 
trix. The samples were centrifuged at 12000 rpm for 
5 min. The supernatant was extracted using 2 ml 
diethyl ether and the organic layer evaporated to 
dryness in a 60°C waterbath. The dried extract was 
reconstituted in 30 gl acetonitrile/H20(1 : 1)solution 
and a 20 gl aliquot of this solution was injected in 
the HPLC. A Beckmann (model 340 organizer) 
HPLC equipped with a Beckmann solvent delivery 
module (model 112) variable wavelength detector 
Table 1. Characteristics of patients 
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Untreated Indomethacin 
treated 
(~ = 20) (n = 8) 
Mean age 48 (23-71) 49 (29-69) 
(years; range) 
Sex (female/male) 15/5 8/0 
Number of stones 12/8 5/3 
(solitary/multiple) 
Cholesterol content 58 + 8 71 +_ 9 
of stone(s) (%) 
(model 165) and a Merck-Hitachi Chromato-inte- 
grator (model D 2500) was used. The analytical 
column was a Merck LiChrospher 60, RP-select B. 
Column temperature was 22°C and the flow rate 
0.8 ml/min. For drug detection the column eluate 
was measured at 254 nm. Sensitivity and linearity 
were tested with standard solutions of indometha- 
cin (0.1, 0.5, 1.0, 2.0, 5.0 ng/ml) disolved in metha- 
nol. Mefenamin (50 ~1) was used as internal stan- 
dard. Recovery was calculated by comparison of 
standard solutions added to drug-free tissue sam- 
ples and standard solutions in methanol. 
Analysis of bile 
Nucleation time was determined as described by 
Holan [6]. For the analysis of biliary lipids samples 
were stored at -70°C. Cholesterol was determined 
colorimetrically with the Liebermann-Burchard re- 
action [1]. Phospholipids were measured as total 
biliary phosphate using the colorimetric assay of 
Fiske and Subbarow [4]. Total bile salts were deter- 
mined by a modified 3~-hydroxysteroid dehydro- 
genase method [20]. The cholesterol saturation in- 
dex of each sample was calculated according to 
Carey [3]. Total proteins were determined using a 
modified Lowry assay according to Jiingst et al. [8]. 
The pH values were determined immediately after 
aspiration in bile samples kept under anearobic 
conditions. 
Mucus glycoproteins were separated from bile 
by gel permeation chromatography. Sepharose 2B- 
CL columns (80 x 2.5 cm) were loaded with 1 ml 
samples of bile and eluted with 0.2 M NaC1 con- 
taining 0.03% sodium azide (NaNj.  Void volume 
was determined with blue dextran 2000. Mucin was 
quantitated in the void volume using the modified 
periodic acid-Schiff assay described by Mantle and 
Allen [13] with pig gastric mucin serving as stan- 
dard. 
930 
Bile viscosity 
Viscosity of gallbladder bile was determined as dy- 
namic viscosity using a Low Shear Rotation Vis- 
cosimeter (Contraves, Zurich, Switzerland). The ro- 
tation viscosimeter allows accurate measurements 
of viscosity of both newtonian and nonnewtonian 
fluids. Dynamic viscosity was calculated from the 
shear forces exerted by a fluid placed in a rotating 
outer cylinder (2T; 12mm diameter x l lmm 
height); shear forces were measured with an inner 
cylinder (2 T; 11 mm diameter). The applied shear 
rate in our experiments was in a range between 10
and l18/s. In all samples the viscosity curve 
reached a plateau at 60/s. Viscosity was calculated 
from triple measurements at this plateau and ex- 
pressed as millipascals times second (mPa.s). 
Statistical analysis 
Values of each group of parametric data are pre- 
sented as mean _+ SEM. Non-parametric data (nu- 
cleation time) are expressed as median and range. 
Group comparison was performed for parametric 
data using unpaired Student's t test and for non- 
parametric data using the Mann-Whitney U test. 
The level of significance was set at P < 0.05. 
Results 
Indomethacin tissue levels 
A close linear detector esponse curve was found 
for indomethacin solutions in a range of 0.1-5 ng/ 
ml. Recovery rates after extraction from drug-free 
mucosal homogenates were 94%. Duplicate analy- 
ses varied less than 5%. No indomethacin was 
measured in the gallbladder mucosa of untreated 
patients. In the treated group indomethacin tissue 
levels were 1.05 _+ 0.4 ng/mg wet weight. 
Table 2. Effect of indomethacin on biliary lipids, total proteins, 
mucin glycoproteins, pH, and nucleation time 
Untreated Indomethacin 
(n = 20) (n = 8) 
Nucleation time 2 (14) 2 (1-14) 
median (range) 
pH 7.5_+0.1 7.4_+0.1 
Cholesterol 21.5 _+ 5.8 16.8 _+ 5.6 
(mmol/1) 
Bile acids 139.8 _+ 20.0 107.9 _+ 22.1 
(mmol/1) 
Phospholipids 43.0_+ 5.8 38.4 _+ 6.9 
(mmol/1) 
Total lipids 10.98 -+ 1.46 9.5 -+ 1.77 
(g/dl) 
Cholesterol 1.29 -+ 0.23 1.51 + 0.18 
saturation index 
Total proteins 5.7 -+ 0.9 5.9 _+ 0.9 
(mg/ml) 
Mucus glycoproteins 0.81 -+ 0.22 0.95 + 0.27 
(gg/ml) 
No significant alterations were observed in response to indome- 
thacin 
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Fig. l. Effect of indomethacin on bile viscosity. Indomethacin 
induced a significant decrease in dynamic viscosity (P < 0.05) 
Analysis of bile 
Despite these ignificant differences in indometha- 
cin tissue concentrations o significant differences 
were found in pH, biliary lipids, or total protein 
content of bile (Table 2). Lithogenicity of bile, as 
determined by nucleation time, was also unaltered 
by indomethacin treatment. Furthermore, in- 
domethacin failed to decrease biliary mucus glyco- 
protein content. However, as shown in Fig. 1 dy- 
namic viscosity was significantly decreased in pa- 
tients receiving indomethacin treatment. 
Discussion 
Indomethacin is a NSAID which inhibits 
prostaglandin synthesis. We measured indometha- 
cin tissue levels in gallbladder mucosa homo- 
genates in patients treated with 75 mg/day for 7 
days. The tissue levels were 1.05_+0.4 ng/mg wet 
weight, a concentration k own to inhibit effectively 
the enzymatic activity of prostaglandin synthetase 
[5,15]. The data collected in this study show that 
this inhibition of prostaglandin synthesis in pa- 
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tients with cholesterol gallstone disease leaves nu- 
cleation time, biliary lipids, cholesterol saturation, 
and proteins unchanged (Table 2). Biliary mucus 
hypersecretion precedes cholesterol crystal forma- 
tion in the prairie dog [111; in this animal high 
doses of aspirin prevent both mucus hypersecretion 
and cholesterol crystal formation [10]. It has there- 
fore been speculated that aspirin may prevent gall- 
stone formation by inhibition of mucus secretion. 
However, in our study, as observed previously in 
both prairie dogs [15] and man [16], indomethacin 
failed to decrease biliary mucus glycoprotein con- 
tent. Therefore, other mechanisms appear to be re- 
sponsible for the beneficial effects of cyclooxyge- 
nase inhibitors in gallstone disease. 
A major finding of our study is the observation 
that indomethacin decreases the viscosity of gall- 
bladder bile. Bile viscosity may play an important 
role in the formation of cholesterol crystals in hu- 
man bile. Since bile flux through the cystic duct is 
inversely correlated to bile viscosity (Poiseuille's 
law), increases in bile viscosity may decrease the 
emptying of the gallbladder, thereby allowing 
cholesterol crystal growth. Recently indomethacin 
has been found to enhance postprandial emptying 
of the gallbladder in patients with c olesterol gall- 
stone disease; indomethacin had no effect on gall- 
bladder motility of healthy volunteers [14]. It is 
tempting to speculate that the indomethacin-in- 
duced decrease in bile viscosity observed in our 
study is the mechanism allowing improved gall- 
bladder emptying. Further studies are needed to 
better define the correlation between gallbladder 
motility and bile viscosity. 
Mucus glycoproteins are major determinants of 
bile viscosity. However, the data of the present 
study indicate that indomethacin decreases bile vis- 
cosity without changing biliary mucus glycoprotein 
content. One possibility to explain this apparent 
discrepancy is that indomethacin alters the 
oligomeric structure of the mucus molecule. The 
correlation between bile viscosity and alterations in
the biliary mucus macromolecule has been careful- 
ly studied by Smith and coworkers [19]. Apparent 
viscosity and the size of the mucin polymer were 
found to be strongly dependent on pH, with a max- 
imum of viscosity at pH 5.5. Our study showed no 
differences inpH in response to indomethacin. This 
makes it unlikely that differences in the degree of 
protonation account for the changes in viscosity 
observed. Studies of intestinal mucus synthesis [9] 
have shown that inhibition of cyclooxygenase with 
aspirin affects glycoprotein synthesis by at least 
two separate mechanisms: firstly, by reduced syn- 
thesis of peptides and, secondly, by reduced 
oligosaccharide assembly of the mucus glyco- 
proteins. Aspirin appears to inhibit specifically 
acetylation of glucosamines [12]. Similar to these 
findings, aspirin-induced inhibition of mucus syn- 
thesis has also been observed in human gallbladder 
explants in two recent studies by Rhodes et al 
[16,17]. Taken together, there is experimental evi- 
dence showing that NSAIDs may interfere with 
mucin synthesis, possibly altering the degree of 
mucin glycosylation. Further studies are needed to 
clarify the effects of NSAIDs on the composition 
and structure of biliary mucins. 
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